The page is the record's research on the issuer — no analyst, no rating, no view. # Kairos Pharma, LTD. (NYSE: KAPA) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Kairos Pharma, LTD., listed on the NYSE under the ticker KAPA. The ISIN is not on the record. The LEI is not on the record. The security type is Corporate. The segment is not on the record. The sector is 2834 Pharmaceutical Preparations. The jurisdiction is United States, Delaware. The issuer is listed and not halted. ## The disclosure read The record holds 33 filings in the twelve months to 2026-11-08, across 27 filing days. The median gap between filing days is 9.0 days, against a median of 6.0 days for the NYSE and 6.0 days for the sector. The latest filing is dated 2026-11-05, which is 3 days before the record date. The latest filing is of type corporate news. The NYSE median filing count is 64.0 and the sector median is 63.0. The NYSE median latency is 4.0 days and the sector median latency is 4.0 days. The filings by type are 4 AGM/EGM, 11 corporate news, 7 directors' dealings, 3 prospectus, 4 regulatory filings and 4 results. ## Auditor The auditor of record is Weinberg & Company P.A., located in Los Angeles, CA. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage The record names 4 research houses on the issuer's investor-relations page: Maxim Group, HC Wainwright, EF Hutton and D. Boral Capital. ## Open research The record holds 3 openly published research notes. Maxim Group published a note dated 2025-09-01, a note dated 2025-06-03 and a note dated 2025-03-27. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's sealed years are 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 11 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://data.sec.gov/submissions/CIK0001962011.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NYSE/KAPA (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx (coverage) - https://kairospharma.com/wp-content/uploads/2025/09/Positive-Interim-Phase-2-Data-For-ENV-105-in-mCRPC-Builds-Co.pdf (open research) - https://kairospharma.com/wp-content/uploads/2025/06/Maxim-Research-Report.pdf (open research) - https://kairospharma.com/wp-content/uploads/2025/03/KAPA.Maxim_.032725.pdf (open research) - https://mcp.us-cm-kg.ai/record/NYSE/KAPA (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NYSE/KAPA · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp